Evaluating External Validity of Oncology Biosimilar Safety Studies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluating External Validity of Oncology Biosimilar Safety Studies

Published:2023-04-06 Issue:4 Volume:6 Page:e235776
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Calip Gregory S.¹²,Altomare Ivy P.¹,Guadamuz Jenny S.¹³

Affiliation:

1. Flatiron Health, New York, New York

2. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois Chicago, Chicago

3. School of Pharmacy, Program on Medicines and Public Health, University of Southern California, Los Angeles

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2803260/calip_2023_ic_230024_1680032319.83295.pdf

Reference10 articles.

1. Cardiac safety and efficacy of SB3 trastuzumab biosimilar for ERBB2-positive early breast cancer: secondary analysis of a randomized clinical trial.;Pivot;JAMA Netw Open,2023

2. ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study.;DaCosta Byfield;J Oncol Pract,2016

3. Real world patterns of care in HER2-overexpressing breast cancer: results of a survey of TEACH clinical trial investigators in 2011.;Chavarri-Guerra;Breast,2017

4. Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer.;Reeder-Hayes;J Clin Oncol,2016

5. Trastuzumab containing regimens for early breast cancer.;Moja;Cochrane Database Syst Rev,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials;NEJM Evidence;2024-03-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3